RESOLUTE is a public-private partnership with 13 partners from academia and industry with an overarching goal: To trigger an escalation in the appreciation and intensity of research on solute carriers (SLCs) worldwide and to establish SLCs as a tractable target class for medical research and development.

RESOLUTE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This article reflects only the authors' views and neither IMI nor the European Union and EFPIA are responsible for any use that may be made of the information contained therein.